Drug Pricing Archives - Pacific Research Institute

Drug Pricing

Commentary

Read the latest on pharmaceutical benefit managers

Biosimilars could save the healthcare system billions

Cost Plus Drug Company CEO Mark Cuban recently pointed out that self-insured businesses could save over $70,000 per employee annually by getting their workers to switch from AbbVie’s blockbuster anti-inflammatory treatment Humira to a lower-cost biosimilar called Yusimry. Humira has a list price of roughly $7,000 per month. Since it lost market exclusivity last year, nine nearly identical copycats have hit ...
Commentary

Read the latest on prescription drug pricing

Biden, Sanders Took on ‘Big Pharma’ and Patients Lost

Speaking at a White House event with Sen. Bernie Sanders, I-Vt., very recently, President Biden crowed about his rapidly progressing scheme to impose price controls on prescription drugs. “Finally — finally we beat Big Pharma,” he said to Sanders. Unfortunately for Americans — and indeed, patients everywhere — the Democrats’ assault on the drug industry ...
Commentary

Read the latest on US drug pricing

Global Collaboration on Reference Models Will Further Depersonalize Healthcare

By Sally Pipes & Wayne Winegarden  Question: What’s worse than government bureaucrats in Washington declaring the value of your medicine? Answer: Bureaucrats from Boston, London, Ottawa and Diemen establishing that value. Unfortunately, this is not a joke. It is the direction that the Institute for Clinical and Economic Review is ...
Commentary

Lawsuit Against Drug Company Could Quash Future Cures

Like most pharmaceutical companies, Gilead Sciences Inc. devotes a huge amount of time and money to making sure its products are safe for patients. The U.S. Food and Drug Administration approved its drugs to fight HIV, and these medications have worked remarkably well. It then developed the next generation of ...
Commentary

Read about the latest drug rationing proposals

Let UK Keep Drug Rationing

Any list of the world’s most inhumane healthcare bureaucracies has to include Britain’s National Institute for Health and Care Excellence at the top. For over two decades, the agency has employed ruthless cost-benefit analyses to effectively deny British patients access to the latest medicines. Now NICE is looking to export its expertise rationing ...
Commentary

Read the latest on Senator Sanders' fight against major pharmaceutical firms

Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming

Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
Commentary

President Biden Is His Own Worst Enemy In The War On Cancer

Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Commentary

Read the latest on Medicare's prescription drug price-setting scheme

Can Constitution Save Us from Drug Price Controls?

AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
Commentary

Reforming PBMs Improves the Drug Market and Thwarts Efforts to Socialize Medicine

By Sally Pipes & Wayne Winegarden There they go again. Free-market advocates are jeopardizing pro-market healthcare reforms based on an inability to recognize how cronyism tars the current industry dynamics. That distinction between companies operating in a free market and companies using cronyism to flourish in a government-dominated market is ...
Commentary

Read the latest on Florida's drug importation plan

Is the FDA opening a door for counterfeit drug trade?

The U.S. Food and Drug Administration gave the go-ahead last month for Florida to import prescription drugs in bulk from Canada. If all goes according to plan, the state government will be able to dispense certain Canadian-sourced drugs to people who receive care through the state Department of Corrections, the ...
Commentary

Read the latest on pharmaceutical benefit managers

Biosimilars could save the healthcare system billions

Cost Plus Drug Company CEO Mark Cuban recently pointed out that self-insured businesses could save over $70,000 per employee annually by getting their workers to switch from AbbVie’s blockbuster anti-inflammatory treatment Humira to a lower-cost biosimilar called Yusimry. Humira has a list price of roughly $7,000 per month. Since it lost market exclusivity last year, nine nearly identical copycats have hit ...
Commentary

Read the latest on prescription drug pricing

Biden, Sanders Took on ‘Big Pharma’ and Patients Lost

Speaking at a White House event with Sen. Bernie Sanders, I-Vt., very recently, President Biden crowed about his rapidly progressing scheme to impose price controls on prescription drugs. “Finally — finally we beat Big Pharma,” he said to Sanders. Unfortunately for Americans — and indeed, patients everywhere — the Democrats’ assault on the drug industry ...
Commentary

Read the latest on US drug pricing

Global Collaboration on Reference Models Will Further Depersonalize Healthcare

By Sally Pipes & Wayne Winegarden  Question: What’s worse than government bureaucrats in Washington declaring the value of your medicine? Answer: Bureaucrats from Boston, London, Ottawa and Diemen establishing that value. Unfortunately, this is not a joke. It is the direction that the Institute for Clinical and Economic Review is ...
Commentary

Lawsuit Against Drug Company Could Quash Future Cures

Like most pharmaceutical companies, Gilead Sciences Inc. devotes a huge amount of time and money to making sure its products are safe for patients. The U.S. Food and Drug Administration approved its drugs to fight HIV, and these medications have worked remarkably well. It then developed the next generation of ...
Commentary

Read about the latest drug rationing proposals

Let UK Keep Drug Rationing

Any list of the world’s most inhumane healthcare bureaucracies has to include Britain’s National Institute for Health and Care Excellence at the top. For over two decades, the agency has employed ruthless cost-benefit analyses to effectively deny British patients access to the latest medicines. Now NICE is looking to export its expertise rationing ...
Commentary

Read the latest on Senator Sanders' fight against major pharmaceutical firms

Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming

Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
Commentary

President Biden Is His Own Worst Enemy In The War On Cancer

Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Commentary

Read the latest on Medicare's prescription drug price-setting scheme

Can Constitution Save Us from Drug Price Controls?

AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
Commentary

Reforming PBMs Improves the Drug Market and Thwarts Efforts to Socialize Medicine

By Sally Pipes & Wayne Winegarden There they go again. Free-market advocates are jeopardizing pro-market healthcare reforms based on an inability to recognize how cronyism tars the current industry dynamics. That distinction between companies operating in a free market and companies using cronyism to flourish in a government-dominated market is ...
Commentary

Read the latest on Florida's drug importation plan

Is the FDA opening a door for counterfeit drug trade?

The U.S. Food and Drug Administration gave the go-ahead last month for Florida to import prescription drugs in bulk from Canada. If all goes according to plan, the state government will be able to dispense certain Canadian-sourced drugs to people who receive care through the state Department of Corrections, the ...
Scroll to Top